Biogen’s FDA Victory Could Bring Major Changes to Alzheimer’s Treatment

About This Source - Bloomberg QuickTake: Now

Bloomberg L.P. is a privately held financial, software, data, and media company headquartered in Midtown Manhattan, New York City.

It was founded by Michael Bloomberg in 1981, with the help of Thomas Secunda, Duncan MacMillan, Charles Zegar, and a 12% ownership investment by Merrill Lynch.

Recent from Bloomberg QuickTake: Now:

  • Has Gold Lost Its Hedge Appeal?
  • Moderna Says Vaccine Is 93% Effective Against Covid After Six Months
  • At Least 10 Dead as Crowded Migrant Van Crashes in Texas: Police
  • Bloomberg Quicktake: Now published this video item, entitled “Biogen’s FDA Victory Could Bring Major Changes to Alzheimer’s Treatment” – below is their description.

    Biogen Inc. took a colossal risk in late 2019. It revived an Alzheimer’s disease drug it had left for dead earlier that year after it appeared to fail two large clinical trials.

    The company wasn’t ready to take no for an answer. Biogen had poured years of effort into developing the therapy, then called aducanumab, and was counting on it as its next big therapeutic advance.

    After months of controversy, Biogen’s bet paid off in spectacular fashion Monday when the U.S. Food and Drug Administration granted the treatment its approval, making it the first new Alzheimer’s drug in almost 20 years and first to attack an underlying process of the disease.

    The potential that the drug will generate billions of dollars in annual sales sent Biogen’s stock soaring, and boosted the shares of rival drugmakers working on similar therapies.

    Bloomberg Quicktake: Now YouTube Channel

    Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

    Leave a Comment